Cisplatin 40 mg/m2

Cisplatin löst eine schwere Nierenfunktionsstörung aus. Dem wirkt der Arzt entgegen, indem er die Urinausscheidung stark fördert. Dazu müssen nach der Gabe von Cisplatin etwa zwei Liter einer geeigneten intravenösen Lösung und gegebenenfalls ein Entwässungsmittel (beispielsweise Mannitol) gegeben werden. Vorherige Seite Nächste Seite. Auf Facebook teilen Auf Twitter teilen Bei. 1 CISplatin 40mg/m2 IV Infusion 500-1000ml NaCl 0.9% over 2 hours (Pre and Post hydration therapy required)** Every 7 days **Pre and post hydration therapy required for CISplatin See local hospital policy recommendations. Suggested prehydration for CISplatin therapy: 1. Administer 10mmol magnesium sulphate (MgSO The aim of this analysis was to investigate feasibility and efficacy of a weekly cisplatin 40 mg/m(2) regimen. Patients and methods: During 08/2001 and 12/2006, 103 patients with squamous head-and-neck cancer received concurrent CRT with intended weekly cisplatin 40 mg/m(2) and were analyzed retrospectively. CRT was definitive for a newly diagnosed primary in 62, postoperative in 16, and for recurrence in 25 patients. Most patients had carcinoma of the hypo- and oropharynx (81%). Patients. In patients with head-and-neck cancer treated with chemoradiotherapy (CRT), a cisplatin-based regimen is often used. Several treatment schedules are accepted with a cumulative cisplatin dose of 200 mg/m2(CisCD200) given during radiotherapy. The aim of this analysis was to investigate feasibility and efficacy of a weekly cisplatin 40 mg/m2regimen

Cisplatin: Nebenwirkungen - Onmeda

Not sure what the question is, because not sure what m2 is. If you have 100 ml and you want to infuse it over 30 min, the rate on the pump would have to be 3.33 ml/min (100ml/30min = 3.33333 ml/min) Cisplatin infusion solutions at a concentration >0.5 mg/mL may result in tissue cellulitis, fibrosis, necrosis, pain, edema, and erythema. • GI toxicity: [US Boxed Warning]: Cisplatin can cause severe nausea and vomiting; use highly effective antiemetic premedication Conclusion: This prospective trial has sufficient data to support the conclusion that concurrent chemoradiotherapy with weekly cisplatin 40 mg/m2 in locally advanced cervical cancer gives good treatment outcomes. When reducing the cisplatin dose to 20 mg/m2, treatment responses were still comparable to the standard, but acute toxicity could be reduced. However, there are insufficient data to assess long term treatment outcomes and late treatment related toxicity, because of the short follow. Bei Cisplatindosen über 60 mg/m2 KOF ist die Anwendung von D-Mannitol (8 g/m2 KOF) unmittelbar vor der ersten Cisplatingabe obligat. Erst nach Eintritt einer minimalen Diurese von 250 ml innerhalb 30 Minuten darf mit der Cisplatinverabreichung begonnen werden. Während der Therapie mit Cisplatin ist auf einen Elektrolytverlust bezüglich Kalium, Magnesium und Calcium und eine entsprechende. Bei Cisplatin-Dosen über 60 mg/m2 KOF ist die intravenöse Anwendung von Mannitol (8 g/m2 KOF = 40 ml/m2 KOF einer 20 %igen Mannitollösung) unmittelbar vor der ersten Gabe von Cisplatin 1 mg/ml Trockensubstanz medac unerlässlich. Erst nach einer Urinausscheidung von wenigstens 250 ml innerhalb von 30 Minuten darf mit der Anwendung von Cisplatin 1 mg/ml Trockensubstanz medac begonnen werden.

Chemoradiotherapy with weekly cisplatin 40 mg/m(2) in 103

1. Int J Clin Oncol. 2019 May;24(5):575-582. doi: 10.1007/s10147-018-01380-z. Epub 2018 Dec 22. A multi-institutional observational study on the effects of three-dimensional radiotherapy and weekly 40-mg/m2 cisplatin on postoperative uterine cervical cancer patients with high-risk prognostic factors Treatment consisted of three cycles of induction chemotherapy (IC) with paclitaxel 175 mg/m2 in a 3-h infusion on d 1, leucovorin (LV) 200 mg/m2 over 20 min immediately followed by FU 400 mg/m2 bolus and then 600 mg/m2 as a 24-h continuous infusion on d 1 and 2 and a cisplatin 75 mg/m2 over 1-h infusion on d 2 every 3 wk. This was then followed by radiation (70 Gy) and weekly cisplatin 40 mg. Cycles are repeated every 21 days for a total of two cycles. Patients then will receive definitive radiotherapy with 3D-CRT or IMRT, and cisplatin (40mg/m2) weekly during external radiotherapy.The radiation dose is 66-76Gy to the GTV, 60Gy to CTV1, and 54Gy to CTV2. Drug: docetaxel, cisplatin, fluorouracil

All patients receive IMRT with concurrent cisplatin 40 mg/m2. Radiation: Intensity Modulated Radiation Therapy (IMRT) 45.0 Gy (intact) or 50.4 Gy (postoperative high-risk) in 1.8 Gy daily fractions over 5-5.5 weeks. Drug: Cisplatin Weekly infusion of 40 mg/m2 (80 mg max) x 5 weeks. Active Comparator: Phase III - A Patients in Phase III, Arm A receive 4-field box RT with concurrent cisplatin 40. Adrenocortical carcinoma (advanced) (off-label use): IV: 40 mg/m 2 on days 3 and 4 every 4 weeks (in combination with doxorubicin, etoposide, and mitotane) (Fassnacht 2012) or 40 mg/m 2 on days 2 and 9 every 4 weeks (in combination with doxorubicin, etoposide, and mitotane) until disease progression or unacceptable toxicity up to a maximum of 6 cycles (Berruti 2005) By contrast, weekly cisplatin at a dose of 40 mg/m 2 was found to be well tolerated and to have acceptable toxicity, despite the large RT fields employed, for the treatment of nasopharyngeal carcinoma . Weekly cisplatin at a dose of 40 mg/m 2 has been the standard schedule for HNC at our institution since 2006. In the present study, we calculated the dose intensity and evaluated the toxicity of this regimen in patients with HNC at our institution retrospectively

Intraperitoneal (IP) in ovarian cancer - 100-200 mg/m2; Intraperitoneal Cisplatin. Used in ovarian cancer after optimal cytoreductive surgery. A single lumen catheter with a port - IP access. CDDP mixed in 1 L of NS and warmed to 37°C, infused through the port via gravity drip as rapidly as possible. A 2 nd litre of NS to help distribute the drug. Complications - myelosuppression. Two cats that received 40 mg/m2 of cisplatin developed pulmonary changes similar to, but less severe than, those seen in the cats that received the higher dose of cisplatin. One cat treated with. 6536 Background: For patients with primary untreated locally advanced head and neck squamous cell carcinoma (PULA-HNSCC), high dose once every 3 weeks cisplatin (HDC; 100 mg/m2) added to curative radiotherapy (RT) prolongs survival, but is associated with severe toxicities. Concurrent chemoradiation (CRT) with low dose weekly cisplatin (LDC; 30-40 mg/m2), carboplatin (C), or RT alone is often. The median cumulative dose was 210 mg/m 2 in the once-a-week arm, suggesting an adequate exposure to cisplatin. 41 Two ongoing phase III trials are comparing 40 mg/m 2 once-a-week cisplatin with 100 mg/m 2 with radiotherapy; we await these results. 30,42. The cost of the improved efficacy of once-every-3-weeks cisplatin CRT was an increase in toxicity T-score analysis showed a 40 percent higher rate of high-grade events for cisplatin, compared to a nominal five-point difference (82 vs. 77 percent) with the traditional reporting method. The specific profile of adverse effects varied by agent, with anemia, hearing loss, nausea, vomiting, neutropenia and kidney injury more common with cisplatin, while rashes were more common among those.

Cisplatin besitzt eine gut belegte, strahlensensibilisierende Wirkung, zu Carboplatin liegen weniger Daten vor. Eine sequentielle konsolidierende Strahlentherapie erhöht die 5-Jahresüberlebensrate um ca. 5%, eine simultane Strahlentherapie um ca.10%. Die Strahlentherapie sollte spätestens mit Beginn des dritten Zyklus gestartet werden, siehe auc The aim of this study is to compare treatment responses and toxicities of concurrent chemo-radiation with weekly and three weekly Cisplatin in locally advanced Head & Neck Cancer. Half of the participants received Cisplatin (40 mg/m2) weekly with radiotherapy, while the other half received Cisplatin (100 mg/m2) thrice weekly with radiotherapy. Radiotherapy continued five days per week for six and half weeks.. Clinical Trials Registry. ICH GCP Cisplatin was administered with pre- and post-hydration containing 10 mEq of potassium chloride in 500 ml of fluid over a 60-min period. Immediately before the administration of cisplatin, mannitol (20%, 200 ml) was administered as forced diuresis over 30 min. And magnesium sulfate (8 mEq) was added to pre-hydration. Results. Forty-four patients were enrolled between April and December 2011. Weekly cisplatin (30-40 mg/m 2) as concurrent chemotherapy. The prescription details of antiemetics were obtained from EMR. The antiemetic prophylaxis received was classified as: Optimal: The antiemetic prophylaxis (antiemetics, dose, and duration) given according to ASCO antiemetic guideline (for high emetogenic potential chemotherapy) with or without any additional antiemetics; Suboptimal. affected. The cat given 40 mg/m2 of cisplatin had pul- monary edema, macrophages in the alveolar septa, eo- sinophilic arteritis, and interstitial pneumonia. One cat that received 60 mg/m2 of cisplatin had multifocal edema on the right side of the ventricular septum in the heart, and one cat had congestion in one kidney. Th

Chemoradiotherapy with Weekly Cisplatin 40 mg/m2 in 103

The rationale for increasing the cisplatin dose is that capillary uptake of cisplatin from peritoneal surfaces is slow and incomplete, resulting in systemic exposure that is prolonged but lower. To evaluate treatment response and acute treatment-related toxicity of concurrent chemoradiotherapy with cisplatin 20 mg/m2 , compared to 40 mg/m2 as the standard, in locally advanced cervical cancer.A prospective randomized controlled trial in Srinagarind Hospital, Faculty of Medicine, Khon Kaen University, Khon Kaen.140 patients, >60 years old with biopsy-proven previously untreated invasive. Over a dose range of 40 to 140 mg cisplatin (cisplatin injection) /m 2 given as a bolus injection or as infusions varying in length from 1 hour to 24 hours, from 10% to about 40% of the administered platinum is excreted in the urine in 24 hours Eine Konzentration von maximal 40 mg Gemcitabin/ml ist einzuhalten; Konzentrationen über 40 mg Gemcitabin/ml können zu einem unvollständigen Auflösen der Trockensubstanz führen und sind daher zu vermeiden. Zum Auflösen von Gemzar 200 Trockensubstanz werden mindestens 5 ml isotonische Kochsalzlösung, für Gemzar 1000 Trockensubstanz mindestens 25 ml isotonische Kochsalzlösung zugegeben; eine weitere Verdünnung ist möglich. In der Regel erweist es sich als vorteilhaft, die notwendige.

The oncologist prescribes a chest x ray a pre chemo

Concurrent weekly cisplatin and radiotherapy in routine

  1. The study showed that tri-weekly cisplatin 75 mg/m2 concurrent to RT is feasible and increase 5-year survival rate significantly compared to weekly cisplatin 40 mg/m2 in patients with locally advanced cervical cancer (66.5% in the weekly arm, 88.7% in the tri-weekly arm; HR=0.375, 95% CI: 0.154-0.914, p= .03). Therefore, in this randomized phase III trial, The investigators intend to confirm.
  2. Feasibility and efficacy of CRT with weekly cisplatin 40 mg/m2 were suboptimal in this analysis. However, the prospects of weekly cisplatin may be its more suitable integration into emerging.
  3. If cisplatin is used in combination therapy, the dose of cisplatin must be reduced. A typical dose is 20 mg/m 2 or more once every 3 to 4 weeks. For treatment of cervical cancer cisplatin is used in combination with radiotherapy. A typical dose is 40 mg/m2 weekly for 6 weeks
  4. Cisplatin dosing information. Usual Adult Dose for Testicular Cancer: 20 mg/m2 by slow IV infusion daily for 5 days per cycle in combination with other approved chemotherapeutic agents Comments:-The dosing presented is manufacturer suggested.-Other doses and combination regimens have been used. Use: For advanced testicular cance
  5. CISPLATIN 40 weekly Gynae SACT regimens Page 11 of 86 with Radiotherapy (Cervix) Indication: Advanced cervical carcinoma, vulval and vaginal carcinoma DRUG REGIMEN Day 1 Pre-hydration regimen CISPLATIN 40mg/m2 (max 70mg) in 1000ml sodium chloride 0.9% infusion over 2 hours (daypatient) or 4 hours (inpatient) Post-hydration regimen Cycle Frequency: Every 7 days whilst having external beam.

Cisplatin (cisplatin) dose, indications, adverse effects

The effect of radiotherapy with concomitant treatment with cisplatin alone has been studied in several phase 2 trials. 16,18,32-40 Two trials reported improvements in local control of tumors and. Concurrent chemoradiotherapy with cisplatin is standard for patients (pts) with loco-regionally advanced squamous cell carcinoma of the head and neck (LA-SCCHN) and for patients with resected SCCHN with high-risk features. The standard regimen includes 3-weekly cisplatin, but weekly regimens are often used to lower toxicity. Reaching a cumulative dose of ≥200 mg/m2 cisplatin was shown being. Die European Organization for the Research and Treatment of Cancer (EORTC) verglich Paclitaxel/Cisplatin mit der Kombination Teniposid (100 mg/m2, Tag 1, 3, 5) und Cisplatin (80 mg/m2, Tag 1.

1. Introduction. Based on the results of several randomized control trials, concurrent chemoradiotherapy (CCRT) is a standard treatment for locally advanced cervical cancer , , , , , and weekly administration of cisplatin (CDDP) at a dose 40 mg/m 2 is accepted globally as a sensitizing agent for CCRT , .In Japan, a phase II study (JGOG 1066 trial) of CCRT using high-dose-rate intracavitary. Materials and methods Weekly gemcitabine at a dose of 125 mg/m2 was given concomitantly with cisplatin at 40 mg/m2 for six cycles with concurrent radiotherapy in primary therapy of stage IB2-IVA cervical cancer. Radiation consisted of 5000 cGy in 25 daily fractions combined with brachytherapy to take point A to about 8600 cGy. Results Using weekly gemcitabine at a dose of 125 mg/m2 with. Docetaxel 40 mg/m² Tag 1+8 Cisplatin 40 mg/m2 Tag 1+8 5-Flurouracil 1500 mg/m²/24h Tag 1+8 alle 21 Tage für 3 Zyklen 2 - Antikörpertherapie mit Cetuximab 400 mg/m² 1 Woche vor RTX, und 250 mg/m² wöchentlich x 6 gleichzeitig RTX 3 - RTX: HART (62 Gy) MRT oder 3D-konforme Strahlentherapie Technik Aktiver Vergleiche Cisplatin 30-40 mg/m2 was infused on days 1, 8, 15, 22, 29, 36 and 43 in the Weekly Group, while cisplatin 80-100 mg/m2 was delivered on days 1, 22 and 43 in the Triweekly Group. The survival outcomes were revealed by the Kaplan-Meier method and Cox regression modelling to measure 5-year overall survival (OS), disease-free survival (DFS), locoregional relapse-free survival (LRFS) and.

225 mg/m2 IV over 3 hours on day 1 followed by carboplatin (AUC of 6) IV over 30 minutes on day 1 repeated every 21 days (CP regimen) for 6 cycles was compared with methotrexate 30 mg/m2 on days 1, 15, and 22, vinblastine 3 mg/m2 IV on days 2, 15, and 22, doxorubicin 30 mg/m2 on day 2, and cisplatin 70 mg/m2 on day 2 (MVAC regimen) in a randomized, phase III trial. In this study, the median. m2/day. Cisplatin was delivered at 20, 30, and 40 mg/m2/day for each dose level of VP-16-213. Dose- rate limiting toxicity was observed first at the VP-16 dose of 50 mg/m2/day and CDDP at 30 mg/m2/ day. At 100 mg/m2/day for VP-16-213, six of 17 courses were associated with life-threatening leukopenia and four of six patients died with sepsis cisplatin 40 mg/m2 on days 1and 15, repeated every 4 weeks, was well tolerated and effective (response rate [RR] = 31.5%) in 35 evaluable patients with platinum-refractory ovarian cancer [41]. The authors found that patients with a progression-free interval less than 3 months after platinum-therapy had lower response rates to gemcitabine and cisplatin (15.8 vs 50%, p = 0.03) than patients with. Mange steder, også i Danmark, giver man cisplatin 40 mg/m2 ugentlig konkomitant med accelereret strålebehandling op til 66-68 Gy, selv om der er sparsomme data på, om dette giver samme effekt.

A typical dose is 40 mg/m 2 weekly for 6 weeks. For warning and precautions to be considered prior to the start of the next treatment cycle (see section 4.4). In patients with renal dysfunction or bone marrow depression, the dose should be reduced adequately (see section 4.3). The cisplatin solution for infusion prepared according to instructions (see section 6.6) should be administered by. Cisplatin 75 mg/m2 als 1- bis 3-stündige Infusion (beide nur an Tag 1), gefolgt von 5-Fluorouracil 750 2mg/m pro Tag als kontinuierliche 24-Stunden-Infusion über 5 Tage, beginnend am Ende der Cisplatin-Infusion. Die Behandlung wird alle 3 Wochen wiederholt. Für die Verabreichung vo N2 - Twenty-nine patients with refractory recurrent small cell carcinoma of the lung were treated with cisplatin (40 mg/m2) and etoposide (200 mg/m2) each day for 3 days, repeated every 3-4 weeks. Fifteen of these patients had received etoposide in their original treatment regimen. Fifteen (52%) of all patients had a major response, as did nine (60%) of the patients with prior exposure to. Die übliche Dosis beträgt 20 mg/m2 oder mehr, einmal alle 3 bis 4 Wochen. Zur Behandlung des Zervixkarzinoms wird Cisplatin in Kombination mit einer Strahlentherapie angewendet. Die übliche Dosis beträgt 40 mg/m 2 wöchentlich über eine Dauer von 6 Wochen. Warnhinweise und Vorsichtsmaßnahmen, die vor Beginn des folgenden Behandlungszyklus.

Concomitant weekly cisplatin and radiotherapy for head and

Phase 2 Trial of Liposomal Doxorubicin (40 mg/m 2) Twelve-year follow-up of a randomized trial comparing cisplatin and cyclophosphamide with cisplatin, doxorubicin and cyclophosphamide in patients with advanced epithelial ovarian cancer. Int J Gynecol Cancer, 6 (1996), pp. 286-290. View Record in Scopus Google Scholar. 6. SA Cannistra. Cancer of the ovary. N Engl J Med, 329 (1993), pp. Cisplatin (cis‐diamminedichloroplatinum; Platinol, Bristol, Syracuse, NY) was administered to 11 cats, divided into three groups of experimental and clinical patients. In group 1, cisplatin was administered at a dose of 60 mg/m2 to four cats. In an attempt to avoid renal toxicity, saline diuresis was induced by administering 0.9% saline solution intravenously at a rate of 20 ml/kg/hr for 4.

Temozolomide, Cisplatin, and Nivolumab in People With

  1. , respectively. Concentrations of these drugs dropped rapidly in two phases. Table 1 Comparison of the MTD in patients and the LDWin mice offour platinum compounds CompoundCisplatin Spiroplatin JM-40 CarboplatinMouse ID, (mg/m2)46.5 20.3 300 495MTD(mg/m2)100 35 1200.
  2. All patients were planned for 6 cycles of weekly paclitaxel (40 mg/m2) and carboplatin (AUC=1) and concomitant radiotherapy, 60 Gy in 6 weeks. The most common side effect was grade 3 and 4 mucositis in 5/6 patients and g-tube placement in 4/6 patients. Five out of 6 patients remain alive without evidence of disease at a mean time of 19 months since completion of therapy. Our pilot study.
  3. Cisplatin 100 mg/m2 q3wks x3c Cisplatin 40 mg/m2 qwk x6c Cetuximab 400 mg/m2 1 wk prior loading -> 250 mg/m2 qwk. What is the induction chemotherapy regimen for laryngeal cancer? Induction cisplatin 100 mg/m2 and 5FU 1000 mg/m2x2c. If PR/CR, 3rd cycle cis/5FU -> RT. What is the chemotherapy regimen for RMS, Wilm's, and Ewing's sarcoma? RMS: VAC (vincristine, actinomycin D, cycloposphamide.
  4. istered. The major hematological toxicities were leukopenia and neutropenia. Grade 4 neutropenia developed in 83.3%, 66.7% and 83.3% of patients at the dose levels of 1, 2 and 3, respectively. The major non.
  5. Cisplatin療法にhydrocortisone succinateを使用し,消化器合併症を4段階評価で査定した.1) Cisplatin 7~20 mg/m2/日×5日間を中心とする多剤併用療法にhydrocortisone 900~1,800 mg/日を使用した場合,嘔気,嘔吐回数,食欲不振の症状は有意に軽減した.2) Cisplatin 30~40 mg/m2/日×1日を中心とする多剤併用療法では,hydrocortisone.

Adjuvante Chemotherapie beim komplett resezierten nicht

  1. und einem maximalen Eingangsdruck von 200 psi eingestellt. Die Injektion wird ferngesteuert. Die Mikropumpe.
  2. alem Ileum, anhängend eine 6 cm lange Appendix und max. 5 cm breites perikolisches Fettgewebe sowie ein 20 × 8 × 1,5 c
  3. istration. The first symptoms of polyneuropathy occurred in 4 of 9 patients after the second course (cumulative dose 400 mg/m2). One month after treatment.
  4. AB - Twenty-nine patients with refractory recurrent small cell carcinoma of the lung were treated with cisplatin (40 mg/m2) and etoposide (200 mg/m2) each day for 3 days, repeated every 3-4 weeks. Fifteen of these patients had received etoposide in their original treatment regimen. Fifteen (52%) of all patients had a major response, as did nine (60%) of the patients with prior exposure to etoposide. Myelotoxicity was moderately severe. The median duration of responses was 3 months (range, 6.
  5. istered by continuous in- travenous infusion in 3000 cc normal saline given over 24 hours on days 1 through 5. Six patients received MAP mitomycin-C, 8 mg/m2; doxorubicin, 40 mg/m2, and cisplatin 60 mg/m2 infused over 2 hours in 1000 ml5% D/0.5 normal saline plus 25 gm mannitol. The one-day program was repeated a
  6. istration of 30-40 mg/m2 of cisplatin to 100 mg/m2of cisplatin on days 1, 22 and 43 for outcomes and toxicity in patients with..

Cisplatin NC 0,5 mg/ml - Gebrauchsinformatio

To investigate the relationships between cisplatin and the related erythropoiesis impairment, 14 patients receiving very-high-dose cisplatin (40 mg/m 2 /day for 5 days) and 17 patients receiving standard-high-dose cisplatin (either a single dose of 100 or 20 mg/m 2 /day for 5 days) entered this study. Iron, ferritin, hemoglobin, and reticulocyte levels were evaluated before, 4 and 6 days after. The default dose of cisplatin was 40 mg/m 2 in 47 patients, 50 mg/m 2 in 40, and 60 mg/m 2 in 35, with a median dose‐intensity of 97.7% (interquartile range: 93.2-100%), 95.2% (79.1-100%), and 88.6% (77.9-98.1%), respectively. No patients were routinely given mannitol or diuretic in this study. Twenty‐six patients required readministration of cisplatin due to cancer recurrence or metastasis during the survey period and we defined these patients as having a history of cisplatin use Cancer Treatment Reviews (1985) 12 (Supplement A), 59-65 High dose cisplatin and high dose carboplatin in refractory ovarian cancer Robert F. Ozols, Brent C. Behrens, Yechiam Ostchega and Robert C. Young Medicine Branch, Division of Cancer Treatment, .National Cancer Institute, Bethesda, Maryland, U.S.A. High dose cisplatin (40 mg/m2 qd x 5) and high dose carboplatin (400 mg/m2 qd x 2) were. Cisplatin in Kombination mit weiteren chemotherapeutischen Präparaten (Kombinationschemotherapie): 20 mg/m² oder höher, einmal alle 3 bis 4 Wochen. Für die Behandlung von Zervixkarzinomen wird Cisplatin im Rahmen einer kombinierten Radio- Chemotherapie verabreicht. Eine typische Dosis liegt bei wöchentlich 40 mg/m2 für 6 Wochen

how do you calculate 40mg/m2 in 100ml in normal saline

  1. Magnesium Depletion in Patients Receiving Cisplatin-based Chemotherapy. Clinical Oncology, 2006. Elizabeth Hodgkinson. R. Coleman. Elizabeth Hodgkinson. R. Coleman. Download PDF. Download Full PDF Package. This paper. A short summary of this paper. 37 Full PDFs related to this paper. READ PAPER. Magnesium Depletion in Patients Receiving Cisplatin-based Chemotherapy.
  2. Purpose Chemoradiation with cisplatin 100 mg/m2 given once every 3 weeks is the standard of care in locally advanced head and neck squamous cell cancer (LAHNSCC). Increasingly, low-dose once-a-week cisplatin is substituted because of perceived lower toxicity and convenience. However, there is no level 1 evidence of comparable efficacy to cisplatin once every 3 weeks. Patients and Methods In.
  3. Cisplatin 50 mg/m2 d I Prednisone 40 mg/m2 d 1-5 BAPP Adriam ycin/cisplatin 1 Lymphocytic CR (9' mo) Mitrov et al. PAC 1 Epithelial CR (12 mo) Campbell et PAC + Vcr I1 - 2 - CR (4+, 20' mo) Klippstein et ~1.~~ Cisplatin, Adriamycin, cyclophosphamide Cisplatin, Adriamycin, cyclophosphamide, 411 1 CR(5, 8+, 29+, 29+ mo) 6/11 PR/(5+, 6, 9, 12, 16+, 22 mo) Fornasiero et al.34 vincristine.
  4. Cisplatin 100 mg/m2 was associated with higher rates of grade ≥3 hematotoxicity (p = 0.004), grade ≥2 renal failure (p = 0.004) and pneumonia/sepsis (p = 0.033). Conclusions: Radiochemotherapy with 100 mg/m2 of cisplatin every 3 weeks resulted in better LRC and OS than weekly doses of 30-40 mg/m2. Given the limitations of a retrospective.
  5. istration of 5-FU addressed toward developing new drugs/combinations (2,000 mg/m2 as a 24-h infusion) and leucovorin (200 mg/ rather than perfor
  6. istered once every 4 weeks for 6 cycles until disease progression or unacceptable toxicity develops. If CISplatin is discontinued before 6 cycles in patients with responding disease, Teysuno® treatment alone can be resumed when the criteria for restarting it are met. Facilities to treat anaphylaxis MUST be present when CISplatin is ad

CISplatin (Professional Patient Advice) - Drugs

Cisplatin in Kombination mit anderen chemotherapeutischen Wirkstoffen (Kombinations-Chemotherapie): - 20 mg/m2 oder mehr, einmal alle 3 bis 4 Wochen. Zur Behandlung des Gebärmutterhalskrebses wird Cisplatin in Kombination mit einer Strahlentherapie angewendet. Die übliche Dosis beträgt 40 mg/m2 wöchentlich über eine Dauer von 6 Wochen Hydration and Antiemetic Protocols for Outpatient Cisplatin (4 h) Day of therapy 1.5 L 5% dextrose 0.45% NaCI 20 mEq kcal over 2 h Furosemide 20 mg IV push 30 min prior to Cisplatin Cisplatin (75 to 100 mg/m2) in 500 mL NaCI over 1 h Antiemetic schedule: Prochlorperazine 30 to 40 mg in 50 mL D5W with initial hydration and 3 h later Diphenhydramine 50 mg IV prior to prochlorperazine. Patients with ovarian or fallopian tube cancers or primary peritoneal carcinoma with platinum/paclitaxel-refractory disease (stable or progressive disease following treatment with these agents or previous objective response <3 months in duration) were treated with liposomal doxorubicin at a dose of 40 mg/m 2 q 4 weeks. Results

Objectives: A dose-finding study of a new cisplatin/vinorelbine schedule was done to increase activity of the combination, and improve compliance of non-small-cell lung cancer patients. Methods: Beginning with cisplatin 40 mg/m 2 on days 1, 2 and vinorelbine 20 mg/m 2 on days 1, 3, increasing dose levels up to the maximum tolerated dose (MTD) were tested in a series of 6-patient cohorts Methods: 50 paclitaxel-pretreated patients with platinum-resistant/refractory ovarian or peritoneal carcinoma who had previously received paclitaxel chemotherapy, were treated with six cycles of gemcitabine 1000 mg/m 2 followed by cisplatin 40 mg/m 2 on days 1 and 15, repeated every 4 weeks. Results: The median platinum-free interval (PFI) was 4 months while the median number of previous treatment lines was 2. Chemotherapy was well tolerated. Objective responses were observed in 31.5% of. studies the applied doses were: cisplatin, 60 mg/m2 (n = 1), 75 mg/m2 (n= I), 100 mg/m2 (n = 3); for spiroplatin, 25 mg/m2 (n = 4), 30 mg/ nr (n = 1); for JM-40, 800 mg/m2 (n = 1), 900 mg/m2 (n = 3), 100

Management of carcinoma cervix

Patients from group 1 received weekly infusions of cisplatin (40 mg/m2) and from group 2 - polyradiosensitization with cisplatin (40 mg/m2) and gemcitabine (75 mg/m2). Results. Chemoradiotherapy. 40 mg/m2 IV on day 1 plus cisplatin 50 mg/m2 IV on day 1, vincristine 0.6 mg/m2 IV on day 3, and cyclophosphamide 700 mg/m2 IV on day 4 repeated every 3 weeks (median of 5 cycles; range, 3 to 7 cycles) resulted in a favorable overall response rate in a nonrandomized study of 37 patients. FDA approved labeling for doxorubicin states to avoid concomitant use with CYP3A4, CYP2D6, and P.

Stage IB1 & node positive, IB2, IIA, IIB, IIIB, or IVA disease cervical cancer PS 0-2 Adequate organ function Cisplatin (40 mg/m2, q1w) + concurrent RT, followed by intracavitary RT Endpoint OS OUTBACK: Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer clinicaltrials.gov - NCT01414608 (Moore K, NRG) Ongoing Weekly Cis. Conclusion: The MTD found in this chemoradiation study was weekly gemcitabine 50 mg/m2 followed by cisplatin 40 mg/m2. The alternative drug sequence has been reported by others to allow higher doses of gemcitabine. However, at this dose level chronic toxicity was observed. Further expansion of the feasibility cohort of this study was suspended pending the efficacy and toxicity results of a. The aim of this study was to assess the efficacy of a lower combination dose, 60 mg/m2 of D and 60 mg/m2 of cisplatin (P), as a treatment for NSCLC. In this randomized, phase III trial, we compared the response rates (RRs) and toxicity profiles of two combination regimens, D/P 75/60 vs. 60/60 mg/m2, to patients with stage IIIB or IV NSCLC. A total of 132 patients were randomized to the 75/60. The maximum tolerated dose was BCNU 40 mg/m2 days 1-3, cisplatin 20 mg/m2 days 1-3 and 29-31, and oral etoposide 50 mg days 1-21 and 29-49 prior to radiation therapy and repeated in 8 weeks with the start of radiation therapy followed by BCNU 200 mg/m2 every 8 weeks for 4 cycles. Median time to progression and survival were 13 and 14 months respectively. Responses occurred in 2 of 9 (22%. Cisplatin in Kombination mit anderen chemotherapeutischen Wirkstoffen (KombinationsChemotherapie): - 20 mg/m2 oder mehr, einmal alle 3 bis 4 Wochen. Zur Behandlung des Gebärmutterhalskrebses wird Cisplatin in Kombination mit einer Strahlentherapie angewendet. Die übliche Dosis beträgt 40 mg/m2 wöchentlich über eine Dauer von 6 Wochen

Weekly cisplatin 20 mg/m2 in patients with carcinoma of

Over a dose range of 40 to 140 mg cisplatin/m 2 given as a bolus injection or as infusions varying in length from 1 hour to 24 hours, from 10% to about 40% of the administered platinum is excreted in the urine in 24 hours. Over five days following administration of 40 to 100 mg/m 2 doses given as rapid, 2- to 3-hour, or 6- to 8-hour infusions, a mean of 35% to 51% of the dosed platinum is. Initially the regimen comprised etoposide 120 mg/m2, days 1-3, doxorubicin 40 mg/m2, day 1, and cisplatin 40 mg/m2, days 2 and 8. GM-CSF was begun on day 4 and continued until recovery of granulocyte counts. Courses were repeated every 21 days. 3 patients were treated at these doses. 5 patients received escalated doses (etoposide 180 mg/m2; doxorubicin 60 mg/m2; cisplatin 60 mg/m2) on this.

Cisplatin in Kombination mit anderen Chemotherapeutika (KombinationsChemotherapie): - 20 mg/m 2 oder mehr, einmal alle 3 bis 4 Wochen. Zur Behandlung des Gebärmutterhalskrebses wird Cisplatin in Kombination mit einer Strahlentherapie angewendet. Die übliche Dosis beträgt 40 mg/m2 wöchentlich über eine Dauer von 6 Wochen Die übliche Dosis beträgt 20 mg/m2 oder mehr, einmal alle 3 bis 4 Wochen. Zur Behandlung des Zervixkarzinoms wird Cisplatin in Kombination mit einer Strahlentherapie angewendet. Die übliche Dosis beträgt 40 mg/m 2 wöchentlich über eine Dauer von 6 Wochen Neben der Standardbestrahlung erhielten die Patienten 1:1 randomisiert intravenös entweder Cisplatin (100 mg/m2 jeweils an Tag 1 und 22 der Strahlentherapie) oder Cetuximab (5-7 Tage vor Bestrahlungsbeginn 400 mg/m2, gefolgt von wöchentlich 250 mg/m2 über 7 Wochen). Die Bestrahlung erfolgte als AIMRT (accelerated intensity modulated radiation therapy), fraktioniert über sechs Wochen. Chemotherapy included bleomycin 15 units/m2 on day 1, etoposide 100 mg/m2 on days 1 through 5, and either high-dose cisplatin 40 mg/m2 on days 1 through 5 (HDPEB; n = 149) or standard-dose cisplatin 20 mg/m2 on days 1 through 5 (PEB; n = 150). Patients were evaluated after four cycles of therapy, and those with residual disease underwent surgery. Those with malignant disease in resected.

PPT - Glioblastoma multiforme PowerPoint Presentation

Carboplatin dose was escalated in 2.7% and 3.6% of cycles in, respectively, 19 and 32 patients in the CD and CP arms. Cumulative number of carboplatin cycles administered in the CP and CD arms was 2,814 and 2,813, respectively. The median treatment duration was longer in the CD arm compared with the CP arm (21 v 16 weeks) PATIENTS AND METHODS: Two hundred seventy-seven patients diagnosed with SCC of the head and neck were randomized to one of three treatments: (1) cisplatin 100 mg/m2 intravenously (IV) on day 1 and 5-FU 1,000 mg/m2 per day for a 96-hour continuous infusion repeated every 21 days; (2) carboplatin 300 mg/m2 IV on day 1 and 5-FU 1,000 mg/m2 per day for a 96-hour continuous infusion repeated every. Cisplatin 40 mg/m 2 IV once weekly and gemcitabine 125 mg/m 2 weekly for 6 weeks with concurrent radiation therapy for total of 50.4 Gy in 28 fractions, followed by brachytherapy 30 to 35 Gy in 96 hours, and then two adjuvant 21-day cycles of cisplatin, 50 mg/m 2 on day 1, plus gemcitabine, 1000 mg/ m 2 on days 1 and 8) Treatment recommendations for metastatic disease. Stage IVB: Patients with.

PPT - BEST OF ASCO LUNG CANCER 2012 PowerPointPPT - Monday Night with Research To Practice: An 8-Part

Twenty-two patients with advanced non-small cell lung cancer (NSCLC), previously unexposed to chemotherapy, were treated with a combination of vincristine (1.4 mg/m 2 iv) on Day 1, cisplatin (40 mg/m 2 iv) on Days 1-3 and etoposide (100 mg/m 2 iv) on Days 1-3 (or 80 mg/m 2 iv on Days 1-3 for patients previously treated with radiation. This trial supports the conclusion of the European. Concomitant boost radiotherapy (1.8 Gy, days 1-38 and 1.5 Gy boost, days 22-38, twice daily with at least a 6-hour interval; total dose 69.9 Gy) and simultaneous cisplatin, 40 mg/m2 weekly, were given. Results. The median treatment duration was 42 days (range, 38-46 days). Toxicity was manageable, with neutropenia grade III/IV and thrombocytopenia grade IV in seven and one patients, and. The MVP regimen contained cisplatin (P) 120 mg/m2 given as a modified hydration technique of Hayes et a1. 12 The cisplatin doses were repeated on day 29 and then every 6 weeks. Vindesine (V) was given as 3 mg/m2 intravenous (IV) bolus weekly for 5 weeks and then every other week. Mitomycin (M) was given as an 8-mg/m2 bolus administered at the time of the first three P doses for a total of. Gemcitabin wurde in einer Dosierung von 500 bis 2592 mg/m2, die über 0,4 bis 1,2 Stunden infundiert wurden, eingesetzt. Cmax betrug fünf Minuten nach Beendigung der Infusion 3,2 bis 45,5 µg/ml. Das Verteilungsvolumen des zentralen Kompartiments wird mit 12,4 l/m² (Frauen) beziehungsweise 17,5 l/m² (Männer) angegeben. Die intraindividuelle. Afatinib alone was given daily for two weeks as lead-in and subsequently given with carboplatin AUC 6 mg/ml min and paclitaxel 175 mg/m2 every 21 days as IC. Afatinib was started at a dose of 20 mg daily and dose escalated using a modified Fibonacci design. After completion of IC, afatinib was discontinued and patients received concurrent cisplatin 40 mg/m2 weekly and standard radiation. 16-40 ml/min 200 mg/m2 i.v. Es liegen unzureichende Daten für die Anwendung von Carboplatin bei Patienten mit einer Creatinin Clearance von 15 ml/min oder weniger vor, um eine Empfehlung für die Behandlung geben zu können. Alle o. a. Dosierungsempfehlungen gelten für den initialen Behandlungszyklus. Die Dosierung der nachfolgenden.

  • Speisekarte Seaside Lübeck.
  • Med Diagnosen.
  • Pie mathe Zeichen.
  • BMW E60 MASK auf CCC.
  • IPhone sendet keine SMS Vodafone.
  • Baby auf Arm schlafen lassen oder ablegen.
  • FC Bayern Münze Gründung.
  • Mahonie verwechslung.
  • Super Mario 64 Remake 2019.
  • Ladungssicherung Anhänger.
  • Bewerbung Anschreiben Nähe zum Wohnort.
  • Ritter compact 1.
  • Suche Spiele kostenlos ohne Anmeldung.
  • Polystyrol BfR.
  • Jigme Namgyel Wangchuck.
  • Sauergras Kreuzworträtsel.
  • Western Digital Software.
  • Loewe Ersatzteile Fernbedienung.
  • Höffner Barsbüttel Restaurant.
  • Hafen Riyadh.
  • Aventoura Jakobsweg.
  • Resident Evil 7 Cheats.
  • Ryan Lochte.
  • Iodat.
  • Babylon berlin 1 3 dvd.
  • Significance level Deutsch.
  • Tagfahrlicht Symbol.
  • Haarlem Niederlande Parken kostenlos.
  • Heeresgruppe Mitte 1944.
  • Heidemann HX 70843 Bedienungsanleitung.
  • Lion Air Absturz.
  • Essen im Glas Shop.
  • Schöller Direct.
  • ENERVIE Mark E.
  • Miele Kühlschrank Ersatzteile Schublade.
  • Wohn und Geschäftshaus Stuttgart.
  • Flug München Chicago heute.
  • Zärtlichkeit Mann.
  • Studie Stress am Arbeitsplatz 2019.
  • Nigeria visa for German citizens.
  • Fahrrad lackieren lassen Dortmund.